18F-FluorThanatrace (PET/CT) in Glioblastoma

Summary

The subject will be a candidate for this imaging study because they have agreed to participate in a treatment study involving TTFields (Optune device), a device that uses low intensity, wave like electrical fields, and a PARP inhibitor drug (niraparib). The research study is being conducted to test how a new radioactive imaging drug called 18F-Fluorthanatrace (18F-FTT) can be used to image sites of recurrent brain cancer before or after new treatment or surgery. 18F-FTT is a drug used with an imaging test called Positron Emission Tomography/Computed Tomography (PET/CT).

Timeline

Start

2020-02-20

Primary completion

2024-06-10

Completion

2024-06-10

Outcome

Outcome not reported

Stopped: “Companion treatment trial closed early with negative results. No imaging study participants completed the full study imaging planned due to logistical difficulties.”

Drugs

Indications